The role of moxifloxacin in tuberculosis therapy
MetadataShow full item record
Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate this treatment and discontinue therapy, increasing the risk of resistance. There is a growing tide of multidrug resistance and few effective antibiotics to tackle the problem. Since the turn of the millennium there has been a surge in interest in developing new therapies for TB and a number of new drugs have been developed. In this review the repurposing of moxifloxacin, an 8-methoxy-fluoroquinolone, for TB treatment is discussed. The evidence that underpins the development of this agent is reviewed. The results of the recently completed phase III trials are summarised and the reasons for the unexpected outcome are explored. Finally, the design of new trials that incorporate moxifloxacin, and that address both susceptible disease and multidrug resistance, is described.
Gillespie , S H 2016 , ' The role of moxifloxacin in tuberculosis therapy ' European Respiratory Review , vol 25 , no. 139 , pp. 19-28 . DOI: 10.1183/16000617.0085-2015
European Respiratory Review
Copyright © ERS 2016. ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
The author gratefully acknowledges the support of the TB Alliance and the European Developing Country Clinical trials Partnership (grant number: IP.2007.32011.011) for their financial support of trials by the author discussed in this work. Funding information for this article has been deposited with FundRef.